Oxycodone and Acetaminophen CII Tablets 7.5 mg/325 mg Recall
Oxycodone and Acetaminophen CII Tablets 7.5 mg/... has been recalled due to failed tablet/capsule specification: there is a potential for the imprint to be missing on tablets.. Consumers who purchased this product should stop using it immediately. Check the official FDA notice for specific lot numbers and return or disposal instructions.
By RecallRadar Editorial Team
Sourced from FDA. Last verified March 4, 2026.
On this page
Free checker
Check if you qualify
See whether your device may qualify for a free repair or replacement program before you spend money.
Check if you qualifyKey facts
- Date announced
- December 16, 2025
- Source agency
- FDA
This recall involves safety concerns. Take action promptly.
✨ Plain-English Summary
Oxycodone and Acetaminophen CII Tablets 7.5 mg/... has been recalled due to failed tablet/capsule specification: there is a potential for the imprint to be missing on tablets.. Consumers who purchased this product should stop using it immediately. Check the official FDA notice for specific lot numbers and return or disposal instructions.
Is This Recall Still Active?
Status: Yes - Active
This recall is currently active. If your device matches the affected models, follow the official instructions as soon as possible.
What's Being Recalled
Quoted source excerpt from the official notice.
Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.
Quick Info
Key facts from the official notice, kept in the article flow for easy cross-checking.
- Brand
- Fda
- Category
- drug
- Source agency
- FDA
- Announced
- December 16, 2025
- Country
- US
- Status
- Active
Who's Affected
Specific models and identifiers listed in the source notice:
Model #1
Lot: 0522J23493, expires: 03/2027.
| # | Model |
|---|---|
| 1 | Lot: 0522J23493, expires: 03/2027. |
Technical model codes are manufacturer identifiers. Match both the product name and model code from your device settings, label, or packaging.
What You Should Do
Follow the remedy path from the official notice using the exact model and serial details above.
- 1## Oxycodone and Acetaminophen CII Tablets USP, 7.5 mg/325 mg, 100 tablets, Rx only, SpecGx LLC, Webster Groves, MO 63119, NDC 0406-0522-
- 2Case label: SpecGx LLC, NDC 0406052201, Exp. 2027/03, Lot: 0522J23493 Agency: FDA | Category: drug Reason: Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets. What to do:
- 3Stop using the product if your lot/model matches.
- 4Check the FDA notice for specifics.
Source & Verification
This page summarizes the official notice and keeps key facts easy to verify.
- Official source
- FDA
- Announced by source
- December 16, 2025
- Last reviewed by RecallRadar
- March 4, 2026
Frequently Asked Questions
Am I affected by this recall?
Check the affected models section on this page. The official notice currently lists Lot: 0522J23493, expires: 03/2027..
What is the remedy for this recall?
## Oxycodone and Acetaminophen CII Tablets USP, 7.5 mg/325 mg, 100 tablets, Rx only, SpecGx LLC, Webster Groves, MO 63119, NDC 0406-0522-01. Case label: SpecGx LLC, NDC 0406052201, Exp. 2027/03, Lot: 0522J23493 Agency: FDA | Category: drug Reason: Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets. What to do: 1. Stop using the product if your lot/model matches. 2. Check the FDA notice for specifics. 3. Follow remedy instructions.
Where can I verify recall details?
Use the official source link in this page to confirm dates, eligibility, and next steps: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
Keep browsing with these internal hubs: FDA recall hub and Food & Drug recall hub.
Official Resources
Use these primary sources for final eligibility and claim instructions.
View official notice from FDASee an inaccuracy?
Help us improve the accuracy of this recall information.
On this page
Free checker
Check if you qualify
See whether your device may qualify for a free repair or replacement program before you spend money.
Check if you qualifyKey facts
- Date announced
- December 16, 2025
- Source agency
- FDA
Related Recalls
Famotidine Injection in Sodium Chloride Injection, 20 mg, 50 mL in GALAXY Single Dose Container, Rx Only, Sterile Nonpyrogenic, Baxter International Inc., Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-5197-41.
CGMP Deviations
Sep 9, 2026
Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100mL Single-Dose Container, Rx only, Sterile, Baxter Healthcare Corporation, Deerfield, IL, 60012 USA, NDC 0338-9640-12.
CGMP Deviations
Sep 9, 2026
Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3814-50.
CGMP Deviations
Sep 9, 2026
Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), 500 mg total, in 50 mL Single Dose Container (24 bags/carton), Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0714-24.
CGMP Deviations
Sep 9, 2026
Nexterone (amiodarone HCI), 360 mg/200 mL (1.8 mg/mL) in GALAXY Single-Dose Container, sterile, Nonpyrogenic, iso-osmotic solution in Dextrose, Baxter Healthcare Corporation, Deerfield, IL 60015, Made in the USA, NDC 43066-360-20.
CGMP Deviations
Sep 9, 2026